Cargando…
Role of aromatase inhibitors in breast cancer
Primarily, the role of the aromatase inhibitors has been investigated in postmenopausal women with breast cancer, although it is also now being assessed in premenopausal patients following ovarian ablation/suppression. Aromatase inhibitors markedly suppress endogenous oestrogens without directly int...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361691/ https://www.ncbi.nlm.nih.gov/pubmed/16100519 http://dx.doi.org/10.1038/sj.bjc.6602688 |
_version_ | 1782153275806580736 |
---|---|
author | Carpenter, R Miller, W R |
author_facet | Carpenter, R Miller, W R |
author_sort | Carpenter, R |
collection | PubMed |
description | Primarily, the role of the aromatase inhibitors has been investigated in postmenopausal women with breast cancer, although it is also now being assessed in premenopausal patients following ovarian ablation/suppression. Aromatase inhibitors markedly suppress endogenous oestrogens without directly interacting with oestrogen receptors, and thus have a different mechanism of action to the antioestrogen, tamoxifen. The inhibitors may be divided into subgroups according to their structure (steroidal and nonsteroidal), and there appears to be a lack of cross-resistance between the classes of aromatase inhibitors enabling them to be used sequentially and potentially to prolong endocrine hormone therapy. In addition, with increased efficacy and favourable safety and tolerability profiles, the aromatase inhibitors are starting to challenge tamoxifen as first choice endocrine treatment in a number of settings. Potential differences in side-effect profiles may appear between the steroidal and nonsteroidal aromatase inhibitors when used in long-term settings. Thus, it has been suggested that the steroidal agents have favourable end organ effects; for example, the steroidal inhibitor, exemestane, has minimal negative effects on bone and lipid metabolism in animal and clinical studies. This paper provides an overview of the current and future roles of aromatase inhibitors for breast cancer treatment. |
format | Text |
id | pubmed-2361691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23616912009-09-10 Role of aromatase inhibitors in breast cancer Carpenter, R Miller, W R Br J Cancer Aromatase Inhibitors–Past, Present and Future Primarily, the role of the aromatase inhibitors has been investigated in postmenopausal women with breast cancer, although it is also now being assessed in premenopausal patients following ovarian ablation/suppression. Aromatase inhibitors markedly suppress endogenous oestrogens without directly interacting with oestrogen receptors, and thus have a different mechanism of action to the antioestrogen, tamoxifen. The inhibitors may be divided into subgroups according to their structure (steroidal and nonsteroidal), and there appears to be a lack of cross-resistance between the classes of aromatase inhibitors enabling them to be used sequentially and potentially to prolong endocrine hormone therapy. In addition, with increased efficacy and favourable safety and tolerability profiles, the aromatase inhibitors are starting to challenge tamoxifen as first choice endocrine treatment in a number of settings. Potential differences in side-effect profiles may appear between the steroidal and nonsteroidal aromatase inhibitors when used in long-term settings. Thus, it has been suggested that the steroidal agents have favourable end organ effects; for example, the steroidal inhibitor, exemestane, has minimal negative effects on bone and lipid metabolism in animal and clinical studies. This paper provides an overview of the current and future roles of aromatase inhibitors for breast cancer treatment. Nature Publishing Group 2005-08 2005-08-15 /pmc/articles/PMC2361691/ /pubmed/16100519 http://dx.doi.org/10.1038/sj.bjc.6602688 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Aromatase Inhibitors–Past, Present and Future Carpenter, R Miller, W R Role of aromatase inhibitors in breast cancer |
title | Role of aromatase inhibitors in breast cancer |
title_full | Role of aromatase inhibitors in breast cancer |
title_fullStr | Role of aromatase inhibitors in breast cancer |
title_full_unstemmed | Role of aromatase inhibitors in breast cancer |
title_short | Role of aromatase inhibitors in breast cancer |
title_sort | role of aromatase inhibitors in breast cancer |
topic | Aromatase Inhibitors–Past, Present and Future |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361691/ https://www.ncbi.nlm.nih.gov/pubmed/16100519 http://dx.doi.org/10.1038/sj.bjc.6602688 |
work_keys_str_mv | AT carpenterr roleofaromataseinhibitorsinbreastcancer AT millerwr roleofaromataseinhibitorsinbreastcancer |